調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024

創薬における人工知能（AI）の世界市場予測（～2024年）

◆タイトル：Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024
◆商品コード：HIT 7445
◆調査・発行会社：MarketsandMarkets
◆発行日：2019年11月27日
◆ページ数：156
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療IT
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,650 ⇒換算￥644,100見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥929,100見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

MarketsandMarkets社は、創薬における人工知能（AI）の世界市場規模が2019年259百万ドルから2024年1343百万ドルまで年平均40.8%成長すると予測しています。当調査レポートでは、創薬における人工知能（AI）の世界市場について調査・分析し、市場概要、提供別（ソフトウェア、サービス）分析、技術別（機械学習、その他の技術）分析、用途別（免疫腫瘍学、神経変性疾患、心血管疾患、代謝疾患、その他の用途）分析、エンドユーザー別（製薬＆バイオテクノロジー企業、受託研究機関、研究センター、学術＆政府機関）分析、地域別（北米、ヨーロッパ、アジア太平洋など）分析、競合環境、企業概要、付録などを含め次の構成でお届け致します。

・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・創薬における人工知能（AI）の世界市場：提供別（ソフトウェア、サービス）
・創薬における人工知能（AI）の世界市場：技術別（機械学習、その他の技術）
・創薬における人工知能（AI）の世界市場：用途別（免疫腫瘍学、神経変性疾患、心血管疾患、代謝疾患、その他の用途）
・創薬における人工知能（AI）の世界市場：エンドユーザー別（製薬＆バイオテクノロジー企業、受託研究機関、研究センター、学術＆政府機関）
・創薬における人工知能（AI）の世界市場：地域別（北米、ヨーロッパ、アジア太平洋など）
・競合環境
・企業概要
・付録

“Growing number of cross-industry collaborations and partnerships and the need to control drug discovery & development costs and reduce the overall time taken in this process are the key factors driving the AI in the drug discovery market.”
The global AI in the drug discovery market is projected to reach USD 1,434 million by 2024 from USD 259 million in 2019, at a CAGR of 40.8% during the forecast period. Growth in this market is mainly driven by growing number of cross-industry collaborations and partnerships, the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications & services, and the impending patent expiry of blockbuster drugs. On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

“The immuno-oncology segment accounted for the largest share in 2019.”
Based on application, the artificial intelligence in the drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular disease, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of 44.6% of the AI in the drug discovery market in 2018, owing to the increasing demand for effective cancer drugs. Neurodegenerative diseases form the fastest-growing application segment, with a CAGR of 42.9% during the forecast period. The ability of AI to discover drugs for complex diseases and the emphasis of market players on providing AI-based platforms for neurological diseases are responsible for the fast growth of this application segment.

“The Research centers and academic & government institutes segment to register the highest growth rate in the forecast period.”
Based on end-user, the AI in the drug discovery market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and research centers and academic, & government institutes. In 2018, the pharmaceutical & biotechnology companies segment accounted for the largest share in the AI in the drug discovery market. AI and machine learning to allow pharmaceutical companies to operate more efficiently and substantially improve success rates at the early stages of drug development. This is one of the major factors driving the growth of this market. Research centers and academic & government institutes are expected to show the highest growth of 43.6%.during the forecast period. The growth of the CROs segment is tied to that of pharmaceutical & biotechnology companies, as the rise in research and production activity will ensure sustained demand for contract services.

“North America to be the largest and the fastest-growing regional market.”
North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. In the North American market, the US is a significant contributor. Also, prominent AI technology providers, such as IBM, Google, Microsoft, NVIDIA, and Intel, are headquartered in the US; their strong presence is a key contributor to market growth. Other drivers include the well-established pharmaceutical industry, high focus on R&D & substantial investment, and the presence of globally leading pharmaceutical companies. These are some of the major factors responsible for the large share and high growth rate of this market.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 (28%), Tier 2 (42%), and Tier 3 (30%)
• By Designation: C-level (30%), D-level (34%), and Others (36%)
• By Region: North America (46%), Europe (25%), Asia (18%), and the RoW (11%)

List of Companies Profiled in the Report
• IBM Corporation (US)
• Microsoft (US), Google (US)
• NVIDIA Corporation (US)
• Atomwise, Inc. (US)
• Deep Genomics (Canada)
• Cloud Pharmaceuticals (US)
• Insilico Medicine (US)
• Benevolent AI (UK)
• Exscientia (UK)
• Cyclica (Canada)
• BIOAGE (US)
• Numerate (US)
• Numedii (US)
• Envisagenics (US)
• twoXAR (US)
• OWKIN, Inc. (US)
• XtalPi (US)
• Verge Genomics (US)
• Berg LLC (US)
Research Coverage:
This report provides a study of the AI in the drug discovery market. It aims at estimating the size and future growth potential of the market across different segments, such as offering, technology, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall AI in drug discovery market and its subsegments. This report will also help stakeholders understand the competitive landscape, and gain insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

【レポートの目次】

1 Introduction (Page No. – 17)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 21)
2.1 Research Data
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary (Page No. – 30)
4 Premium Insights (Page No. – 35)
4.1 Market Overview
4.2 Market, By Offering (2019–2024)
4.3 Market for Machine Learning, By Type & Region (2018)
4.4 Market: Geographic Growth Opportunities
5 Market Overview (Page No. – 39)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Growing Number of Cross-Industry Collaborations and Partnerships
5.2.1.2 Need to Control Drug Discovery & Development Costs and Reduce Time
5.2.1.3 Patent Expiry
5.2.2 Market Opportunities
5.2.2.1 Growing Biotechnology Industry
5.2.2.2 Emerging Markets
5.2.3 Market Challenges
5.2.3.1 Limited Availability of Data Sets
6 Market, By Offering (Page No. – 43)
6.1 Introduction
6.2 Software
6.2.1 Benefits Offered By Software in Drug Discovery & Strong Demand Among End Users are Driving Market Growth
6.3 Services
6.3.1 Services Segment to Witness the Highest Growth During the Forecast Period
7 Market, By Technology (Page No. – 48)
7.1 Introduction
7.2 Machine Learning
7.2.1 Increasing Adoption of Ml By Research Centers & Pharmaceutical Companies to Support the Growth of This Segment
7.2.2 Deep Learning
7.2.3 Supervised Learning
7.2.4 Reinforcement Learning
7.2.5 Unsupervised Learning
7.2.6 Other Machine Learning Technologies
7.3 Other Technologies
8 Market, By Application (Page No. – 63)
8.1 Introduction
8.2 Immuno-Oncology
8.2.1 High Prevalence of Cancer and Shortage in the Supply of Cancer Drugs are the Key Factors Driving Market Growth
8.3 Neurodegenerative Diseases
8.3.1 AI is Being Used to Resolve Existing Challenges in Neurological Disease Drug Development
8.4 Cardiovascular Disease
8.4.1 Rising Demand for Cvd Drugs is Driving Market Growth
8.5 Metabolic Diseases
8.5.1 Role of AI in Uncovering Small-Molecule Therapies is Driving Its Adoption in This Segment
8.6 Other Applications
9 Market, By End User (Page No. – 74)
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.2.1 Rising Demand for Solutions to Cut Time and Costs of Drug Development have Drawn End-User Attention to AI
9.3 Contract Research Organizations
9.3.1 Growing Trend of Outsourcing Provides Significant Opportunities for Cros
9.4 Research Centers and Academic & Government Institutes
9.4.1 This Segment is Expected to Grow at the Highest CAGR During the Forecast Period
10 Market, By Region (Page No. – 82)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 Strong Economy and Trend of Early Adoption of Technologies are Driving Market Growth in the US
10.2.2 Canada
10.2.2.1 Growing Research on AI Technologies and Emergence of New Ai-Based Start-UPS Will Support the Market in Canada
10.2.3 Mexico
10.2.3.1 Government Initiatives Will Support Market Growth in Mexico
10.3 Europe
10.3.1 UK
10.3.1.1 The UK Holds the Largest Share of the European Market
10.3.2 Germany
10.3.2.1 Government Support and Favorable Training Programs are Major Market Drivers in Germany
10.3.3 France
10.3.3.1 Strong Government Support and Favorable Strategies & Initiatives Form Key Drivers of the Market in France
10.3.4 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.1.1 Japan Dominates the APAC Market for AI in Drug Discovery
10.4.2 China
10.4.2.1 Growing Cmos Market and Cross-Industry Collaborations are Factors Responsible for the Growth of the Market in China
10.4.3 India
10.4.3.1 Steady Adoption of AI Technologies Will Drive Market Growth in India
10.4.4 Rest of Asia Pacific
10.5 Rest of the World
11 Competitive Landscape (Page No. – 114)
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Dynamic Differentiators
11.3.3 Innovators
11.3.4 Emerging Companies
11.4 Competitive Situation and Trends
11.4.1 Product Launches and Enhancements
11.4.2 Expansions
11.4.3 Acquisitions
11.4.4 Other Strategies
12 Company Profiles (Page No. – 121)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 Microsoft Corporation
12.2 NVIDIA Corporation
12.3 IBM Corporation
12.4 Google (A Subsidiary of Alphabet Inc.)
12.5 Atomwise, Inc.
12.6 Deep Genomics
12.7 Cloud Pharmaceuticals, Inc.
12.8 Insilico Medicine
12.9 Benevolentai
12.10 Exscientia
12.11 Cyclica
12.12 Bioage
12.13 Numerate
12.14 Numedii, Inc.
12.15 Envisagenics
12.16 Twoxar, Incorporated
12.17 Owkin, Inc.
12.18 Xtalpi, Inc.
12.19 Verge Genomics
12.20 Berg LLC
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. – 149)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details

List of Tables (150 Tables)
Table 1 Indicative List of Collaborations and Partnerships (2017–2019)
Table 2 Indicative List of Drugs Losing Patent in 2019
Table 3 Artificial Intelligence in Drug Discovery Market, By Offering, 2017–2024 (USD Million)
Table 4 Market for Software, By Region, 2017–2024 (USD Million)
Table 5 North America: Market for Software, By Country, 2017–2024 (USD Million)
Table 6 Europe: Market for Software, By Country, 2017–2024 (USD Million)
Table 7 APAC: Market for Software, By Country, 2017–2024 (USD Million)
Table 8 Market for Services, By Region, 2017–2024 (USD Million)
Table 9 North America: Market for Services, By Country, 2017–2024 (USD Million)
Table 10 Europe: Market for Services, By Country, 2017–2024 (USD Million)
Table 11 APAC: Market for Services, By Country, 2017–2024 (USD Million)
Table 12 Market, By Technology, 2017–2024 (USD Million)
Table 13 Market for Machine Learning, By Type, 2017–2024 (USD Million)
Table 14 Market for Machine Learning, By Region, 2017–2024 (USD Million)
Table 15 North America: Market for Machine Learning, By Country, 2017–2024 (USD Million)
Table 16 Europe: Market for Machine Learning, By Country, 2017–2024 (USD Million)
Table 17 APAC: Market for Machine Learning, By Country, 2017–2024 (USD Million)
Table 18 Market for Deep Learning, By Region, 2017–2024 (USD Million)
Table 19 North America: Market for Deep Learning, By Country, 2017–2024 (USD Million)
Table 20 Europe: Market for Deep Learning, By Country, 2017–2024 (USD Million)
Table 21 APAC: Market for Deep Learning, By Country, 2017–2024 (USD Million)
Table 22 Market for Supervised Learning, By Region, 2017–2024 (USD Million)
Table 23 North America: Market for Supervised Learning, By Country, 2017–2024 (USD Million)
Table 24 Europe: Market for Supervised Learning, By Country, 2017–2024 (USD Million)
Table 25 APAC: Market for Supervised Learning, By Country, 2017–2024 (USD Million)
Table 26 Market for Reinforcement Learning, By Region, 2017–2024 (USD Million)
Table 27 North America: Artificial Intelligence in Drug Discovery Market for Reinforcement Learning, By Country, 2017–2024 (USD Million)
Table 28 Europe: Market for Reinforcement Learning, By Country, 2017–2024 (USD Million)
Table 29 APAC: Market for Reinforcement Learning, By Country, 2017–2024 (USD Million)
Table 30 Market for Unsupervised Learning, By Region, 2017–2024 (USD Million)
Table 31 North America: Market for Unsupervised Learning, By Country, 2017–2024 (USD Million)
Table 32 Europe: Market for Unsupervised Learning, By Country, 2017–2024 (USD Million)
Table 33 APAC: Market for Unsupervised Learning, By Country, 2017–2024 (USD Million)
Table 34 Market for Other Machine Learning Technologies, By Region, 2017–2024 (USD Million)
Table 35 North America: Market for Other Machine Learning Technologies, By Country, 2017–2024 (USD Million)
Table 36 Europe: Market for Other Machine Learning Technologies, By Country, 2017–2024 (USD Million)
Table 37 APAC: Market for Other Machine Learning Technologies, By Country, 2017–2024 (USD Million)
Table 38 Market for Other Technologies, By Region, 2017–2024 (USD Million)
Table 39 North America: Market for Other Technologies, By Country, 2017–2024 (USD Million)
Table 40 Europe: Market for Other Technologies, By Country, 2017–2024 (USD Million)
Table 41 APAC: Market for Other Technologies, By Country, 2017–2024 (USD Million)
Table 42 Market, By Application, 2017–2024 (USD Million)
Table 43 Indicative List of Initiatives in Immuno-Oncology Drug Development
Table 44 Market for Immuno-Oncology, By Region, 2017–2024 (USD Million)
Table 45 North America: Market for Immuno-Oncology, By Country, 2017–2024 (USD Million)
Table 46 Europe: Market for Immuno-Oncology, By Country, 2017–2024 (USD Million)
Table 47 APAC: Market for Immuno-Oncology, By Country, 2017–2024 (USD Million)
Table 48 Market for Neurodegenerative Diseases, By Region, 2017–2024 (USD Million)
Table 49 North America: Market for Neurodegenerative Diseases, By Country, 2017–2024 (USD Million)
Table 50 Europe: Artificial Intelligence in Drug Discovery Market for Neurodegenerative Diseases, By Country, 2017–2024 (USD Million)
Table 51 APAC: Market for Neurodegenerative Diseases, By Country, 2017–2024 (USD Million)
Table 52 Indicative List of Developments in Cardiovascular Drug Development
Table 53 Market for Cardiovascular Diseases, By Region, 2017–2024 (USD Million)
Table 54 North America: Market for Cardiovascular Diseases, By Country, 2017–2024 (USD Million)
Table 55 Europe: Market for Cardiovascular Diseases, By Country, 2017–2024 (USD Million)
Table 56 APAC: Market for Cardiovascular Diseases, By Country, 2017–2024 (USD Million)
Table 57 Market for Metabolic Diseases, By Region, 2017–2024 (USD Million)
Table 58 North America: Market for Metabolic Diseases, By Country, 2017–2024 (USD Million)
Table 59 Europe: Market for Metabolic Diseases, By Country, 2017–2024 (USD Million)
Table 60 APAC: Market for Metabolic Diseases, By Country, 2017–2024 (USD Million)
Table 61 Market for Other Applications, By Region, 2017–2024 (USD Million)
Table 62 North America: Market for Other Applications, By Country, 2017–2024 (USD Million)
Table 63 Europe: Market for Other Applications, By Country, 2017–2024 (USD Million)
Table 64 APAC: Market for Other Applications, By Country, 2017–2024 (USD Million)
Table 65 Market, By End User, 2017–2024 (USD Million)
Table 66 Indicative List of Developments
Table 67 Market for Pharmaceutical & Biotechnology Companies, By Region, 2017–2024 (USD Million)
Table 68 North America: Market for Pharmaceutical & Biotechnology Companies, By Country, 2017–2024 (USD Million)
Table 69 Europe: Market for Pharmaceutical & Biotechnology Companies, By Country, 2017–2024 (USD Million)
Table 70 APAC: Artificial Intelligence in Drug Discovery Market for Pharmaceutical & Biotechnology Companies, By Country, 2017–2024 (USD Million)
Table 71 Indicative List of Collaborations With Cros
Table 72 Market for Contract Research Organizations, By Region, 2017–2024 (USD Million)
Table 73 North America: Market for Contract Research Organizations, By Country, 2017–2024 (USD Million)
Table 74 Europe: Market for Contract Research Organizations, By Country, 2017–2024 (USD Million)
Table 75 APAC: Market for Contract Research Organizations, By Country, 2017–2024 (USD Million)
Table 76 Indicative List of Research Collaborations
Table 77 Market for Research Centers and Academic & Government Institutes, By Region, 2017–2024 (USD Million)
Table 78 North America: Market for Research Centers and Academic & Government Institutes, 2017–2024 (USD Million)
Table 79 Europe: Market for Research Centers and Academic & Government Institutes, 2017–2024 (USD Million)
Table 80 APAC: Market for Research Centers and Academic & Government Institutes, 2017–2024 (USD Million)
Table 81 Market, By Region, 2017–2024 (USD Million)
Table 82 North America: Market, By Country, 2017–2024 (USD Million)
Table 83 North America: Market, By Offering, 2017–2024 (USD Million)
Table 84 North America: Market, By Technology, 2017–2024 (USD Million)
Table 85 North America: Market, By Application, 2017–2024 (USD Million)
Table 86 North America: Market, By End User, 2017–2024 (USD Million)
Table 87 Indicative List of Strategic Developments
Table 88 US: Market, By Offering, 2017–2024 (USD Million)
Table 89 US: Market, By Technology, 2017–2024 (USD Million)
Table 90 US: Market, By Application, 2017–2024 (USD Million)
Table 91 US: Market, By End User, 2017–2024 (USD Million)
Table 92 Canada: Market, By Offering, 2017–2024 (USD Million)
Table 93 Canada: Market, By Technology, 2017–2024 (USD Million)
Table 94 Canada: Market, By Application, 2017–2024 (USD Million)
Table 95 Canada: Market, By End User, 2017–2024 (USD Million)
Table 96 Mexico: Market, By Offering, 2017–2024 (USD Million)
Table 97 Mexico: Market, By Technology, 2017–2024 (USD Million)
Table 98 Mexico: Market, By Application, 2017–2024 (USD Million)
Table 99 Mexico: Market, By End User, 2017–2024 (USD Million)
Table 100 Europe: Market, By Country, 2017–2024 (USD Million)
Table 101 Europe: Market, By Offering, 2017–2024 (USD Million)
Table 102 Europe: Market, By Technology, 2017–2024 (USD Million)
Table 103 Europe: Market, By Application, 2017–2024 (USD Million)
Table 104 Europe: Market, By End User, 2017–2024 (USD Million)
Table 105 Indicative List of Strategic Developments
Table 106 UK: Market, By Offering, 2017–2024 (USD Million)
Table 107 UK: Artificial Intelligence in Drug Discovery Market, By Technology, 2017–2024 (USD Million)
Table 108 UK: Market, By Application, 2017–2024 (USD Million)
Table 109 UK: Market, By End User, 2017–2024 (USD Million)
Table 110 Germany: Market, By Offering, 2017–2024 (USD Million)
Table 111 Germany: Market, By Technology, 2017–2024 (USD Million)
Table 112 Germany: Market, By Application, 2017–2024 (USD Million)
Table 113 Germany: Market, By End User, 2017–2024 (USD Million)
Table 114 France: Market, By Offering, 2017–2024 (USD Million)
Table 115 France: Market, By Technology, 2017–2024 (USD Million)
Table 116 France: Market, By Application, 2017–2024 (USD Million)
Table 117 France: Market, By End User, 2017–2024 (USD Million)
Table 118 RoE: Market, By Offering, 2017–2024 (USD Million)
Table 119 RoE: Market, By Technology, 2017–2024 (USD Million)
Table 120 RoE: Market, By Application, 2017–2024 (USD Million)
Table 121 RoE: Market, By End User, 2017–2024 (USD Million)
Table 122 APAC: Market, By Country, 2017–2024 (USD Million)
Table 123 APAC: Market, By Offering, 2017–2024 (USD Million)
Table 124 APAC: Market, By Technology, 2017–2024 (USD Million)
Table 125 APAC: Market, By Application, 2017–2024 (USD Million)
Table 126 APAC: Market, By End User, 2017–2024 (USD Million)
Table 127 Japan: Market, By Offering, 2017–2024 (USD Million)
Table 128 Japan: Market, By Technology, 2017–2024 (USD Million)
Table 129 Japan: Market, By Application, 2017–2024 (USD Million)
Table 130 Japan: Market, By End User, 2017–2024 (USD Million)
Table 131 China: Market, By Offering, 2017–2024 (USD Million)
Table 132 China: Artificial Intelligence in Drug Discovery Market, By Technology, 2017–2024 (USD Million)
Table 133 China: Market, By Application, 2017–2024 (USD Million)
Table 134 China: Market, By End User, 2017–2024 (USD Million)
Table 135 India: Market, By Offering, 2017–2024 (USD Million)
Table 136 India: Market, By Technology, 2017–2024 (USD Million)
Table 137 India: Market, By Application, 2017–2024 (USD Million)
Table 138 India: Market, By End User, 2017–2024 (USD Million)
Table 139 RoAPAC: Market, By Offering, 2017–2024 (USD Million)
Table 140 RoAPAC: Market, By Technology, 2017–2024 (USD Million)
Table 141 RoAPAC: Market, By Application, 2017–2024 (USD Million)
Table 142 RoAPAC: Market, By End User, 2017–2024 (USD Million)
Table 143 RoW: Market, By Offering, 2017–2024 (USD Million)
Table 144 RoW: Market, By Technology, 2017–2024 (USD Million)
Table 145 RoW: Artificial Intelligence in Drug Discovery Market, By Application, 2017–2024 (USD Million)
Table 146 RoW: Market, By End User, 2017–2024 (USD Million)
Table 147 Product Launches and Enhancements, 2016–2019
Table 148 Expansions, 2016–2019
Table 149 Acquisitions, 2016–2019
Table 150 Other Strategies, 2016–2019

★調査レポート[創薬における人工知能（AI）の世界市場予測（～2024年）] ( Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 / HIT 7445) 販売に関する免責事項
[創薬における人工知能（AI）の世界市場予測（～2024年）] ( Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 / HIT 7445) についてEメールでお問い合わせ

※関連データはありません。


◆H&Iグローバルリサーチ株式会社のお客様（例）◆